SCHEMBL5583175

SCHEMBL5583175

Cc1ccc2c(c1)[nH]c1c2ccc2cn[nH]c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM3 Q86V86 1/20 0.47
MPL P40238 2/20 0.46
KIF11 P52732 4/20 0.45
MAPT P10636 3/20 0.42
ITK Q08881 6/20 0.42
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
GABRA4 P48169 1/20 0.41
GABRE P78334 1/20 0.41
GABRA6 Q16445 1/20 0.41
GABRG1 Q8N1C3 1/20 0.41
GABRG3 Q99928 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5583293 0.89 ACHE (0.46) PIM3KIF11MAPTITKGABRP
SCHEMBL5583310 0.79 KIF11 (0.58) PIM3MPLKIF11MAPTGABRP
SCHEMBL844918 0.74 PIM3 (0.56) PIM3MPLKIF11ITKRXFP1
SCHEMBL5583274 0.74 NOS1 (0.51) PIM3MAPTGABRPGABRDGABRA1
SCHEMBL5583287 0.74 PIM3 (0.60) PIM3GABRPGABRDGABRA1GABRB1
SCHEMBL14366529 0.74 MAPT (0.45) MAPTKDM4EALDH1A1HSD17B10
SCHEMBL20060303 0.74 KDM4E (0.59) MAPTCDK2KDM4EALDH1A1MEN1
SCHEMBL12354 0.74 KDM4E (0.59) MAPTCDK2KDM4EALDH1A1MEN1
SCHEMBL5582982 0.74 KDM4E (0.54) PIM3MAPTRXFP1CCNB2CDK1
SCHEMBL5583145 0.73 MAPT (0.47) KIF11MAPTGABRPGABRDGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US claimed
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer IGF1R, KDR, ERBB2 PIM3 474/4885MPL 1102/4885KIF11 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.